

September 23, 2023

To,

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: 512529

Symbol: SEQUENT

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (USFDA) had an inspection of the Company's manufacturing facility situated at Visakhapatnam, Andhra Pradesh from September 18, 2023 to September 22, 2023. At the end of the inspection, we have been issued a Form 483 with one observation. The observation is procedural in nature. We will respond to the USFDA within the stipulated timeline and work closely with them to address the observation at the earliest.

The Company remains committed to maintaining the highest standards of quality, safety and compliance.

Please take the information on record.

Thanking you,

Yours faithfully

For **Sequent Scientific Limited**

Krunal Shah

Company Secretary & Compliance Officer

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | **CIN:** L99999MH1985PLC036685

<http://www.sequent.in>